Skip to main content
Full access
Letters
Published Online: 1 October 2013

Torsade de Pointes Associated With Laxative Abuse in a Patient Receiving Methadone

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
To the Editor: The risk factors of torsade de pointes are: drug-induced Q-Tc prolongation, female gender, hypokalemia, unrecognized congenital long Q-T syndrome (LQTS), and predisposing DNA polymorphisms.1,2 These risk factors have not been studied in patients receiving methadone, a drug associated with Q-Tc interval prolongation, with a dose–effect relationship.2,3 Also, drug-induced Q-Tc prolongation can be a potentially dangerous adverse effect of medication combinations. Most of the torsade de pointes caused by polypharmacy, including methadone, were reported in patients with human immunodeficiency virus (HIV). We report the case of a patient on stable methadone treatment, without HIV infection, whose condition suddenly worsened with hidden laxative abuse.

Case Report

“Ms. A,” a 46-year-old, white woman, had a history of cocaine and heroin dependence (discontinued 2 years ago, with negative urinary drug analysis) and cannabis dependence. She received methadone maintenance treatment, 80–200 mg/day for 4 years. The ECG recorded 3 months before the emergency department presentation was normal: Q-Tc 396 msec.
During her hospitalization to reduce methadone doses, while she received methadone 200 mg/day, the patient presented sudden death and was resuscitated after an episode of torsade de pointes. In the emergency department, the initial ECG on presentation showed ventricular tachycardia with torsade de pointes and Q-Tc 491 msec. The torsade de pointes resolved spontaneously. In the cardiac intensive care unit, she developed another episode of torsade de pointes. During hospitalization in the cardiology department, repetition of the ECG showed increased Q-Tc of 500 msec. The echocardiography found a left ventricular dysfunction (left ventricular ejection fraction: 20%−25%). Laboratory testing revealed hypokalemia (2.7 mmol/l). A treatment including ramipril and bisoprolol was started, and the patient’s condition improved. An empty box of laxatives (bisacodyl) was found in the patient's room. The patient acknowledged taking laxative to lose weight. She fulfilled DSM-IV-TR criteria for eating disorder, NOS.

Discussion

The cause of torsade de pointes is generally multifactorial. Our patient presented several risk factors for torsade de pointes: 1) female gender; 2) high doses of methadone; and 3) severe hypokalemia induced by hidden laxative abuse. Also, since the patient’s maternal grandmother died from sudden death, a congenital LQTS cannot be excluded.
This case highlights the need for carefully monitoring patients treated with methadone for potentially dangerous Q-T prolongation, which can occur even after the patients have been on therapy for some time. Patients should be informed that laxative use/abuse could lead to hypokalemia and increase their risk of developing a prolonged Q-T interval.3 ECG should be repeated to look for Q-Tc prolongation, but that may not be sufficient. Clinical investigations and ionograms could help to detect surreptitious laxative abuse.

References

1.
Sauer AJ, Newton-Cheh C: Clinical and genetic determinants of torsade de pointes risk. Circulation 2012; 125:1684–1694
2.
Stringer J, Welsh C, Tommasello A: Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Health Syst Pharm 2009; 66:825–833
3.
Krantz MJ, Martin J, Stimmel B, et al.: Q-Tc interval screening in methadone treatment. Ann Intern Med 2009; 150:387–395

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: E24
PubMed: 24247876

History

Published online: 1 October 2013
Published in print: Fall 2013

Authors

Affiliations

Xavier Laqueille, M.D.
Service d’Addictologie du Centre Hospitalier Sainte-AnneParis, France
Christophe Genin, M.D.
Service d’Addictologie du Centre Hospitalier Sainte-AnneParis, France
Benjamin Pitrat, M.D.
Service d’Addictologie du Centre Hospitalier Sainte-AnneParis, France
Aline Lupuyau, M.D.
Service d’Addictologie de la Polyclinique La ConcordeAlfortville, France
Alain Dervaux, M.D., Ph.D.
Service d’Addictologie de la Polyclinique La ConcordeAlfortville, France

Notes

Correspondence: Dr Alain Dervaux; e-mail: [email protected]

Competing Interests

Conflict of interest: Alain Dervaux has received honoraria for lectures from Bristol-Myers Squibb, Lundbeck, and Lilly. The other authors declare no conflicts of interest.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share